Precision diagnostics firm Strata Oncology said on Tuesday that it has obtained Medicare coverage for its Strata Select molecular profiling test for patients with solid tumors that meet specified coverage criteria.
Strata Select features the Immunotherapy Response Score, a multivariate biomarker algorithm to predict the benefit for anti-PD-1/PD-L1 checkpoint inhibitor immunotherapy. The Immunotherapy Response Score integrates relevant biological factors (tumor mutational burden, PD-L1, PD-1, and tumor microenvironment components) into a score to predict immunotherapy benefit across all solid tumors. A validation of the Immunotherapy Response Score was published earlier this year in Communications Medicine; additional data were presented at the 2023 AACR Annual Meeting and are planned for presentation at the 2023 ASCO Annual Meeting.
Strata Oncology said that the test, which is available for clinical use, received a positive coverage determination from Palmetto MolDX under the Next-Generation Sequencing for Solid Tumors policy.